SynAct Pharma AB (OSTO:SYNACT) EV-to-EBIT : -1.27 (As of Jun. 18, 2024)

View and export this data going back to 2016. Start your Free Trial

What is SynAct Pharma AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, SynAct Pharma AB's Enterprise Value is kr242.36 Mil. SynAct Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-190.94 Mil. Therefore, SynAct Pharma AB's EV-to-EBIT for today is -1.27.

The historical rank and industry rank for SynAct Pharma AB's EV-to-EBIT or its related term are showing as below:

OSTO:SYNACT' s EV-to-EBIT Range Over the Past 10 Years
Min: -95.29 Med: 0 Max: 0
Current: -1.27

OSTO:SYNACT's EV-to-EBIT is ranked worse than
100% of 427 companies
in the Biotechnology industry
Industry Median: 9.37 vs OSTO:SYNACT: -1.27

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. SynAct Pharma AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr256.28 Mil. SynAct Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-190.94 Mil. SynAct Pharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -74.50%.

SynAct Pharma AB EV-to-EBIT Historical Data

The historical data trend for SynAct Pharma AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SynAct Pharma AB EV-to-EBIT Chart

SynAct Pharma AB Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-4.57

-34.12

-48.01

-21.64

-1.13

SynAct Pharma AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EV-to-EBIT	Get a 7-Day Free Trial															-15.49	-14.54	-3.28	-1.13	-1.34

Competitive Comparison of SynAct Pharma AB's EV-to-EBIT

For the Biotechnology subindustry, SynAct Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

SynAct Pharma AB's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, SynAct Pharma AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where SynAct Pharma AB's EV-to-EBIT falls into.

SynAct Pharma AB EV-to-EBIT Calculation

SynAct Pharma AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	242.356	/	-190.937
	=	-1.27

SynAct Pharma AB's current Enterprise Value is kr242.36 Mil.
SynAct Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-190.94 Mil.

SynAct Pharma AB (OSTO:SYNACT) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

SynAct Pharma AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 )	=	EBIT	/	Enterprise Value (Q: Mar. 2024 )
	=	-190.937	/	256.27844
	=	-74.50 %

SynAct Pharma AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr256.28 Mil.
SynAct Pharma AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-190.94 Mil.

SynAct Pharma AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of SynAct Pharma AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

SynAct Pharma AB (OSTO:SYNACT) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SynAct Pharma AB (OSTO:SYNACT) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

8F8:Germany

Address

Sheelevagen 2, Lund, SWE, 223 81

Website

https://www.synactpharma.se

SynAct Pharma AB is a clinical-stage biotech company focused on resolving inflammation through selective activation of the melanocortin system. The company has a platform technology based on a new class of drug candidates that target acute exacerbations in chronic inflammatory diseases with the primary aim of stimulating natural healing mechanisms. AP1189, the company's lead drug candidate, is being evaluated in three Phase 2 clinical programs regarding rheumatoid arthritis, idiopathic membranous glomerulonephritis and virus-induced respiratory failure.

SynAct Pharma AB (OSTO:SYNACT) Headlines

No Headlines